Evidence map›Paper›PMID 32170842›Full record

ArticlePhysiological reports2020

FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.

Amar B Singh, Bin Dong, Fredric B Kraemer, Jingwen Liu

Open access · goldAbstract read
In one paragraph

Article in Physiological reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Protective Effects ofJournal of microbiology and biotechnology · 2026
    Article
  2. Research Status and Latest Progress in the Regulatory Mechanisms of ABCA1.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
  5. Role of FXR in Renal Physiology and Kidney Diseases.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amar B SinghVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.ORCID 0000-0002-7677-2424
Bin DongVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Fredric B KraemerVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.ORCID 0000-0003-2468-7807
Jingwen LiuVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
VA Palo Alto Health Care System · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Targeting PCSK9 Transcription to Combat Hypercholesterolemia by BerberineR01AT006336 · NCCIH · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI LIU, JINGWEN · 2012 to 2016
$1.7M
BLRD VA I01 BX000398BLRD VA I01 BX001419NCCIH NIH HHS R01 AT006336NIDDK NIH HHS P30 DK116074NIH HHS P30DK116074NIH HHS R01AT006336-01A1ORD VA I01BX000398ORD VA I01BX001419
6 · The paper itself

Abstract

Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR-B1 expression. Here we show that hepatic SR-B1 depletion by an adenovirus expressing Sr-b1 shRNA (Ad-shSR-B1) attenuated these beneficial effects of OCA in mice on a chow diet. The mRNA levels of ABC cholesterol transporter genes (Abca1, Abcg1, Abcg5, and Abcg8) were unchanged in the liver of hepatic SR-B1-depleted mice regardless of OCA treatment; however, a modest increase in Abca1, Abcg5, and Abcg8 mRNA levels was observed in the ileum of vehicle-treated control mice and Abca1 and Abcg8 mRNA levels were increased more by OCA administration. OCA treatment of Sr-b1 knock out (KO) mice (Sr-b1-/-) fed a normal chow diet (NCD) displayed a similar lack of transhepatic cholesterol movement, as well as a modest increase in the levels of ileum cholesterol transporter expression. However, OCA treatment of Sr-b1 KO mice fed a cholesterol-enriched diet reduced circulating cholesterol and increased fecal cholesterol output to comparable degrees to that of wild-type (WT) mice, and these effects were accompanied by substantial elevations of mRNA levels of Abca1, Abcg1, Abcg5, and Abcg8 in the ileum of Sr-b1 KO mice. Our studies suggest that FXR activation stimulates intestinal cholesterol excretion and reduces diet-induced hyperlipidemia through increased expression of ileal cholesterol transporters when hepatic SR-B1-mediated cholesterol movement is absent.

Indexed as

Diet, High-FatAnimalsATP-Binding Cassette TransportersChenodeoxycholic AcidCholesterolHyperlipidemiasLiverMaleMice, Inbred C57BLMice, KnockoutReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearScavenger Receptors, Class BATP-Binding Cassette TransportersChenodeoxycholic AcidCholesterolobeticholic acidReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearScarb1 protein, mouseScavenger Receptors, Class Bbile acidcholesterol transporterfecal cholesterolFXRobeticholic acidSR-B1

Identifiers

PMID32170842
PMCPMC7070099
OpenAlexW3012329206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.